RecruitingNot applicableNCT07191431

A Clinical Study on the Efficacy and Safety of Methotrexate (MTX) or Thiotepa (for MTX Intolerance) or Temozolomide (TMZ) Combined With Orelabrutinib and Selinexor in Relapsed/Refractory Primary or Secondary Central Nervous System Lymphoma(SELINA)

Studying Lymphoma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Ruijin Hospital
Intervention
Selinexor+Orelabrutinib+Methotrexate/Thiotepa/Temozolomide(drug)
Enrollment
25 target
Eligibility
14-80 years · All sexes
Timeline
20252029

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT07191431 on ClinicalTrials.gov

Other trials for Lymphoma

Additional recruiting or active studies for the same condition.

See all trials for Lymphoma

← Back to all trials